Acutaas Chemicals Share Price Target 2026, 2027, 2028, 2029, 2030
- Market Cap
- ₹26,369 Cr
- Book Value
- ₹202
- Stock P/E
- 68.3
- Dividend Yield
- 0.05%
- ROE
- 24.1%
- ROCE
- 31.6%
- PEG Ratio
- 1.49
- EV/EBITDA
- 45.9
Fundamentals from Screener.in, as of 5 Aug 2026. Live price via Yahoo Finance.
Acutaas Chemicals share price today
Acutaas Chemicals (NSE: ACUTAAS — renamed from Ami Organics in 2025) runs two structural stories through one P&L. The base: advanced pharma intermediates for blockbuster molecules, a qualified-supplier business with global generics and innovator clients. The kicker: battery electrolyte additives (VC/FEC chemistry) as India’s cell-manufacturing buildout localises its supply chain. Three-year profit CAGR: 62%, with 37.1% operating margins that scream specialty rather than commodity.
At 68.3× with a PEG of 1.49, our universe tags it wait — both stories are real; the price already believes them both.
Two S-curves, one plant network
Pharma intermediates compound on molecule wins: once designed into a drug’s supply chain, revenue persists for the product’s life, and Acutaas keeps adding molecules ahead of patent cliffs. Electrolyte additives are earlier-curve: global supply concentrates in China, every Indian gigafactory needs local qualification, and Acutaas moved first among Indian listings. If even one story delivers fully, today’s earnings base doubles; the multiple prices substantial delivery already.
Watch-items: electrolyte-additive qualification wins (binary, chunky), pharma client concentration, capex execution across sites, and the 32.7% promoter holding — low, a legacy of the founder-dilution path.
The numbers
From our research universe snapshot (5 Aug 2026):
| Metric | Value |
|---|---|
| Market cap | ₹26,369 Cr |
| P/E (TTM) | 68.3 |
| EV/EBITDA | 45.9 |
| Operating margin | 37.1% |
| ROE / ROCE | 24.1% / 31.6% |
| Debt to equity | 0.02 |
| Sales CAGR (5y) | 31.5% |
| Profit CAGR (5y) | 45.8% |
| Promoter holding | 32.7% |
| EPS (TTM) | ₹47.23 |
Acutaas Chemicals share price target 2026 to 2030
EPS base ₹47.23 (TTM). Bear: battery story stalls, pharma alone — 12% growth, multiple at 34×. Base: both engines compound — 20% growth at 50×. Bull: electrolyte additives scale with India’s gigafactories — 28% growth at 66×.
| Year | Bear (34×, +12%) | Base (50×, +20%) | Bull (66×, +28%) |
|---|---|---|---|
| 2026 | ₹1,800 | ₹2,835 | ₹3,990 |
| 2027 | ₹2,015 | ₹3,400 | ₹5,105 |
| 2028 | ₹2,255 | ₹4,080 | ₹6,535 |
| 2029 | ₹2,525 | ₹4,895 | ₹8,370 |
| 2030 | ₹2,830 | ₹5,875 | ₹10,710 |
From ₹3,224, the base case is ≈ +82% over four and a half years; the bear is −12%. High-multiple dual-story stocks reward two things: entering on doubt and verifying delivery quarterly. The range below handles the first; our monthly reviews handle the second.
Reasons to own Acutaas (at the right price)
- Two structural S-curves — pharma intermediates today, battery chemistry tomorrow.
- 37% operating margins prove specialty pricing power.
- Qualified-supplier stickiness in both businesses once designed in.
- 31.6% ROCE with near-zero debt funds both build-outs internally.
- First-mover among Indian listings in electrolyte-additive localisation.
The risks: 68× needs both stories to keep delivering, battery qualification cycles are slow and binary, and the 32.7% promoter stake offers less anchor than typical.
Should you buy at the current price?
The live buy range below is for members — where two stories cost one story’s price.
FAQ
What is the Acutaas Chemicals share price target for 2030? Base case ≈ ₹5,875 (50× on 20% compounded growth), bear ≈ ₹2,830, bull ≈ ₹10,710. Arithmetic above.
Why did Ami Organics change its name? The 2025 rebrand to Acutaas reflects the widened portfolio beyond the original pharma-intermediates identity — the businesses and management continue unchanged.
What are electrolyte additives? Specialty molecules (like vinylene carbonate) added to lithium-ion electrolytes to extend battery life. Tiny volumes, high value, dominated by China — exactly the import-substitution profile India’s cell buildout must localise.
When are Acutaas’s next results? Track the exact date on our results calendar.
This article is research and education, not personalised investment advice. We are not SEBI-registered advisers. Price targets are scenario arithmetic, not promises. Do your own research and consult a registered adviser before acting.